null

null

null

null

null

null

null

null

null

0.04x Total Debt / Equity (Conservative)

Minimal debt leverage; primary burn is equity-funded R&D. A 200bps rate rise marginally increases cost of any future debt but negligibly impacts current operations.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Lutetium-177 isotope sourcing (limited global reactor supply) and specialized radiolabeling contract manufacturers, both concentrated in North America and Europe.

Essentially no international revenue currently; pre-commercial stage means sovereign currency devaluation exposure is effectively zero across all markets.

U.S.-only clinical operations; no material international revenue. Currency devaluation exposure is negligible until post-approval commercialization.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single-source radioisotope suppliers (e.g., NorthStar Medical Radioisotopes) likely represent non-substitutable input; high vendor lock risk given limited Lu-177 production capacity globally.

Clinical-stage biopharma; no cloud-dependent revenue product. AWS/GCP termination would disrupt internal data management but not halt core drug development operations.

Secondary reliance on CRO/CDO partners for trial data management; cloud disruption manageable within 60–90 days by migrating to alternative providers.

Low API coupling risk; company uses standard clinical trial and lab informatics platforms with no proprietary API dependency generating revenue.

Revenue model is drug development/licensing; common enterprise profits not derived from a token or investment contract. Howey Test risk is not applicable.

Very High

Limited GDPR/CCPA exposure; clinical trial patient data governed by HIPAA and FDA regulations. Small patient dataset scale reduces regulatory penalty magnitude.

Negligible antitrust risk; pre-commercial niche oncology radiopharmaceutical company with no dominant market share or pricing power to attract scrutiny.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/grant/milestone-based; no recurring subscription revenue. Potential future royalty streams post-licensing deals remain speculative.

Milestone payments, licensing deals, and eventual drug sales; primary near-term vector is partnership/licensing revenue from phospholipid drug conjugate (PDC) platform.

No commercial product yet; future pricing likely modeled on radiopharmaceutical comps (~$20K–$50K per treatment course), subject to payer negotiation and CMS reimbursement.

Moderate-to-high potential pricing power if CLR 131 gains approval in niche indications with limited competition; constrained by payer pushback on high-cost oncology agents.

Post-commercial gross margins estimated 60–75%, consistent with specialty oncology radiopharmaceuticals, assuming contract manufacturing scale efficiencies.

No free-rider leakage problem; proprietary PDC platform protected by patents. Clinical candidates not freely replicable by competitors.

Revenue growth is sublinear to headcount; a licensing/royalty model post-approval requires minimal headcount addition. Current ~30-person team is lean and scalable.

Marginal cost of revenue growth is low post-approval; incremental licensing or royalty revenue requires minimal additional fixed cost investment.

Not applicable; Cellectar does not operate a franchise network.

At 10x scale (post-approval), customer acquisition shifts to oncology practice/hospital formulary adoption; CAC likely $50K–$150K per institutional account via medical affairs.

No meaningful network effect; drug efficacy and physician adoption are independent of user base size. Network effects are not applicable to this model.

-145.5% Return on Assets (Negative equity)

Moderate resilience; late-stage cancer treatment demand is relatively inelastic, but funding access and partnership deal flow are cyclically sensitive.

Oncology-focused biopharma partners and potential acquirers (licensing customers); secondary payers/hospital systems post-commercialization.

Hematology/oncology clinicians and hospital cancer centers as end-user prescribers; concentration risk high given niche rare cancer indications.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is being deployed into future-state infrastructure (IND/NDA clinical programs, radiopharmaceutical manufacturing scale-up), not legacy operations maintenance.

0001279704

CLRB